ProCE Banner Activity


State of the ART: Safety and Tolerability Data Discussions From CROI 2023


In this video module, hear updates on ART safety and tolerability from CROI 2023 including LA CAB + RPV thigh injections, ISL effect on lymphocyte counts, assessment of drug-drug interactions in transgender women, and ART-related weight gain.

Pharmacists: 0.50 contact hour (0.05 CEUs)

Nurses: 0.50 Nursing contact hour

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: May 09, 2023

Expiration: May 08, 2024



David Koren

David Koren, PharmD, MPH

Clinical Pharmacist Specialist
Temple University Health System
Philadelphia, Pennsylvania

Aadia Rana

Aadia Rana, MD

Associate Professor of Medicine
Division of Infectious Diseases
University of Alabama at Birmingham
1917 Clinic
Birmingham, Alabama

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Janssen Therapeutics Division of Janssen Products and ViiV Healthcare.

Janssen Therapeutics, Division of Janssen Products, LP

ViiV Healthcare

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with HIV infection.

Program Learning Goal

The goal of this activity is to improve learners’ competence in individualizing ART regimens for HIV by examining patient characteristics and the latest ART safety and tolerability data.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply appropriate ART modification strategies for patients experiencing adverse events or poor tolerability while receiving a virologically suppressive regimen
  • Incorporate patient characteristics into ART strategies to optimize HIV care for special populations


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

David Koren, PharmD, MPH

Clinical Pharmacist Specialist
Temple University Health System
Philadelphia, Pennsylvania

David Koren, PharmD, MPH: consultant/advisor/speaker: Gilead sciences, ViiV Healthcare.

Aadia Rana, MD

Associate Professor of Medicine
Division of Infectious Diseases
University of Alabama at Birmingham
1917 Clinic
Birmingham, Alabama

Aadia Rana, MD: researcher: Merck.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 09, 2023, through May 08, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.

2. Read the target audience, learning objectives, and faculty disclosures.

3. View and study the content in its entirety.

4. Submit answers to the posttest questions and evaluation questions online.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Nursing Continuing Professional Development 
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-129-H01-P

Type of Activity
: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.